1. Introduction
1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
4. Europe Monoclonal Antibodies Market Landscape
4.1 Market Overview
4.2 Porter's Five Forces Analysis
- 4.2.1 Bargaining Power of Suppliers
- 4.2.2 Bargaining Power of Buyers
- 4.2.3 Threat of New Entrants
- 4.2.4 Competitive Rivalry
- 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
- 4.3.1 Raw Material Suppliers
- 4.3.2 Manufacturers
- 4.3.3 Distributors/Suppliers
- 4.3.4 End Users
5. Europe Monoclonal Antibodies Market – Key Market Dynamics
5.1 Growth Drivers
- 5.1.1
- 5.1.2 Growing demand for targeted therapies
- 5.1.3 Rising prevalence of chronic diseases
- 5.1.4 Advancements in biopharmaceutical research
5.2 Market Opportunities
- 5.2.1
- 5.2.2 Expansion in immunotherapy applications
- 5.2.3 Development of biosimilar monoclonals
- 5.2.4 Demand in autoimmune disease treatment
5.3 Future Trends
- 5.3.1
- 5.3.2 Increased focus on personalized medicine
- 5.3.3 Advancements in antibody-drug conjugates
- 5.3.4 Growth in oncology monoclonal antibodies
5.4 Impact of Drivers and Restraints
6. Europe Monoclonal Antibodies Market Regional Analysis
6.1 Europe Monoclonal Antibodies Market Overview
6.2 Europe Monoclonal Antibodies Market Revenue 2019-2028 (US$ Million)
6.3 Europe Monoclonal Antibodies Market Forecast Analysis
7. Europe Monoclonal Antibodies Market Analysis – by Source
7.1 Human
- 7.1.1 Overview
- 7.1.2 Human: Europe Monoclonal Antibodies Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Humanized
- 7.2.1 Overview
- 7.2.2 Humanized: Europe Monoclonal Antibodies Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Chimeric
- 7.3.1 Overview
- 7.3.2 Chimeric: Europe Monoclonal Antibodies Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Murine
- 7.4.1 Overview
- 7.4.2 Murine: Europe Monoclonal Antibodies Market – Revenue and Forecast to 2031 (US$ Million)
8. Europe Monoclonal Antibodies Market Analysis – by Production Method
8.1 In-Vitro
- 8.1.1 Overview
- 8.1.2 In-Vitro: Europe Monoclonal Antibodies Market – Revenue and Forecast to 2028 (US$ Million)
8.2 In-Vivo
- 8.2.1 Overview
- 8.2.2 In-Vivo: Europe Monoclonal Antibodies Market – Revenue and Forecast to 2028 (US$ Million)
9. Europe Monoclonal Antibodies Market Analysis – by Indication
9.1 Cancer
- 9.1.1 Overview
- 9.1.2 In-Vivo: Europe Monoclonal Antibodies Market – Revenue and Forecast to 2028 (US$ Million)
9.2 Autoimmune Diseases
- 9.2.1 Overview
- 9.2.2 In-Vivo: Europe Monoclonal Antibodies Market – Revenue and Forecast to 2028 (US$ Million)
9.3 Infectious Diseases
- 9.3.1 Overview
- 9.3.2 In-Vivo: Europe Monoclonal Antibodies Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Inflammatory Diseases
- 9.4.1 Overview
- 9.4.2 In-Vivo: Europe Monoclonal Antibodies Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Microbial Diseases
- 9.5.1 Overview
- 9.5.2 In-Vivo: Europe Monoclonal Antibodies Market – Revenue and Forecast to 2028 (US$ Million)
10. Europe Monoclonal Antibodies Market – Europe Analysis
10.1 Europe
- 10.1.1 Europe Monoclonal Antibodies Market Breakdown, by Key
Country, 2022 and 2028 (%)
- 10.1.1.1 Europe Monoclonal Antibodies Market – Revenue and
Forecast Analysis – by Country
- 10.1.1.1 UK:
Europe Monoclonal Antibodies Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.1.1 UK: Europe Monoclonal Antibodies Market Breakdown, by Source
- 10.1.1.1.2 UK: Europe Monoclonal Antibodies Market Breakdown, by Production Method
- 10.1.1.1.3 UK: Europe Monoclonal Antibodies Market Breakdown, by Indication
- 10.1.1.2 Germany:
Europe Monoclonal Antibodies Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.2.1 Germany: Europe Monoclonal Antibodies Market Breakdown, by Source
- 10.1.1.2.2 Germany: Europe Monoclonal Antibodies Market Breakdown, by Production Method
- 10.1.1.2.3 Germany: Europe Monoclonal Antibodies Market Breakdown, by Indication
- 10.1.1.3 France:
Europe Monoclonal Antibodies Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.3.1 France: Europe Monoclonal Antibodies Market Breakdown, by Source
- 10.1.1.3.2 France: Europe Monoclonal Antibodies Market Breakdown, by Production Method
- 10.1.1.3.3 France: Europe Monoclonal Antibodies Market Breakdown, by Indication
- 10.1.1.4 Russia:
Europe Monoclonal Antibodies Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.4.1 Russia: Europe Monoclonal Antibodies Market Breakdown, by Source
- 10.1.1.4.2 Russia: Europe Monoclonal Antibodies Market Breakdown, by Production Method
- 10.1.1.4.3 Russia: Europe Monoclonal Antibodies Market Breakdown, by Indication
- 10.1.1.5 Italy:
Europe Monoclonal Antibodies Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.5.1 Italy: Europe Monoclonal Antibodies Market Breakdown, by Source
- 10.1.1.5.2 Italy: Europe Monoclonal Antibodies Market Breakdown, by Production Method
- 10.1.1.5.3 Italy: Europe Monoclonal Antibodies Market Breakdown, by Indication
- 10.1.1.6 Rest of Europe:
Europe Monoclonal Antibodies Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.6.1 Rest of Europe: Europe Monoclonal Antibodies Market Breakdown, by Source
- 10.1.1.6.2 Rest of Europe: Europe Monoclonal Antibodies Market Breakdown, by Production Method
- 10.1.1.6.3 Rest of Europe: Europe Monoclonal Antibodies Market Breakdown, by Indication
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Europe Monoclonal Antibodies Market Industry Landscape
12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments
13. Company Profiles
13.1 Novartis AG
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Pfizer Inc.
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 GlaxoSmithKline plc.
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Amgen Inc
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 DAIICHI SANKYO COMPANY, LIMITED
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 F. Hoffmann-La Roche Ltd.
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 AstraZeneca
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Eli Lilly and Company
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Bayer AG
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Bristol-Myers Squibb Company
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
14.1 About Business Market Insights